Pancreatic cancer surgery upgrade: remove the whole pancreas, then transplant its own cells to avoid diabetes

NCT ID NCT05116072

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a two-step surgery for people with pancreatic or related cancers. Instead of the standard partial removal, doctors remove the entire pancreas and then transplant the patient's own insulin-making cells into the liver. The goal is to prevent a common complication (pancreatic leak) that often stops chemotherapy, while also avoiding severe diabetes. The trial will enroll 36 adults and track how many complete their planned chemotherapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

islet cells (transplanted into the liver)

What this could lead to

If it works, this approach could help more patients finish chemotherapy after pancreatic cancer surgery while avoiding severe diabetes.

What could go wrong

This is an early-phase trial with only 36 people. The surgery is major, and the islet transplant may not always work well, leaving some patients dependent on insulin.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA OF THE PANCREAS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenocarcinoma ampulla of vater adenocarcinoma duodenal adenocarcinoma pancreatic adenocarcinoma pancreatic intraductal papillary-mucinous neoplasm with an associated invasive carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hop Claude Huriez Chu Lille

    RECRUITING

    Lille, 59037, France

    Contact Phone: •••-•••-••••